Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16220129 | 0.95 | MAP3K12 (0.84) | MAP3K12DLK1 | |
| SCHEMBL16220027 | 0.93 | MAP3K12 (1.00) | MAP3K12DLK1 | |
| SCHEMBL16220134 | 0.91 | MAP3K12 (0.92) | MAP3K12DLK1 | |
| SCHEMBL16220262 | 0.91 | MAP3K12 (0.90) | MAP3K12DLK1 | |
| SCHEMBL16220130 | 0.90 | MAP3K12 (0.87) | MAP3K12DLK1 | |
| SCHEMBL16220294 | 0.89 | MAP3K12 (0.86) | MAP3K12DLK1 | |
| SCHEMBL22239456 | 0.88 | MAP3K12 (0.91) | MAP3K12 | |
| SCHEMBL16220120 | 0.88 | MAP3K12 (0.92) | MAP3K12DLK1 | |
| SCHEMBL16220048 | 0.87 | MAP3K12 (0.89) | MAP3K12 | |
| SCHEMBL16220255 | 0.87 | MAP3K12 (1.00) | MAP3K12DLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991977-B1 | C-LINKED HETEROCYCLOALKYL SUBSTITUTED PYRIMIDINES AND THEIR USES | HOFFMANN LA ROCHE (CH) | 2020-07-22 | — | — | EP | claimed |
| EP-2991977-B1 | C-LINKED HETEROCYCLOALKYL SUBSTITUTED PYRIMIDINES AND THEIR USES | HOFFMANN LA ROCHE (CH) | 2020-07-22 | — | — | EP | disclosed |
| EP-2991977-B1 | C-LINKED HETEROCYCLOALKYL SUBSTITUTED PYRIMIDINES AND THEIR USES | HOFFMANN LA ROCHE (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-9868720-B2 | C-linked heterocycloaklyl substituted pyrimidines and their uses | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868720-B2 | C-linked heterocycloaklyl substituted pyrimidines and their uses | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160046608-A1 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses | GENENTECH, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046608-A1 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses | GENENTECH, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2014177524-A1 | C-LINKED HETEROCYCLOALKYL SUBSTITUTED PYRIMIDINES AND THEIR USES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046608-A1 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses | TYMS, DPYD, TYMP | MAP3K12 1825/4885DLK1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.